AIM IMMUNOTECH INC (AIM)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$0.15-5.53%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · AIM
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Equels. “Over the past year, we have strengthened our financial position while completing enrollment and Ampligen dosing in the metastatic pancreatic cancer Phase 2 clinical trial – critical steps as…
Stated in 1 of 1 supplied quarters. Management reported: “Equels. “Over the past year, we have strengthened our financial position while completing enrollment and Ampligen dosing in the metastatic pancreatic cancer Phase 2 clinical trial – critical steps as we move toward an anticipated Phase 3 study in metastatic pancreatic cancer.” “We anticipate DURIPANC data on clinical benefit in Q1 2027 and on Overall Survival – the gold standard data point in oncology – in Q3 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Equels. “Over the past year, we have strengthened our financial position while completing enrollment and Ampligen dosing in the metastatic pancreatic cancer Phase 2 clinical trial – critical steps as…”
|| ● | Planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease , consistent with the Company’s strategy of pursuing non-dilutive funding opportu…
Stated in 1 of 1 supplied quarters. Management reported: “|| ● | Planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease , consistent with the Company’s strategy of pursuing non-dilutive funding opportunities for select infectious disease programs while maintaining pancreatic cancer as its primary strategic focus.” “|| ● | Planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease , consistent with the Company’s strategy of pursuing non-dilutive funding opportunities for select infectious disease programs while maintaining pancreatic cancer as its primary strategic focus.”
“|| ● | Planning government-focused initiatives to evaluate Ampligen’s antiviral potential against Ebola virus disease , consistent with the Company’s strategy of pursuing non-dilutive funding opportu…”
|| ● | Successfully regained full compliance with NYSE American’s continued listing standards .
Stated in 1 of 1 supplied quarters. Management reported: “|| ● | Successfully regained full compliance with NYSE American’s continued listing standards .” “The NYSE American formally notified the Company on June 12, 2026, confirming that the Company had successfully addressed and resolved all deficiencies related to Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.”
“|| ● | Successfully regained full compliance with NYSE American’s continued listing standards .”
|| ● | Research and development expenses for the three months ended June 30, 2026 were approximately $589,000, compared to $1.2 million during the same period in 2025.
Stated in 1 of 1 supplied quarters. Management reported: “|| ● | Research and development expenses for the three months ended June 30, 2026 were approximately $589,000, compared to $1.2 million during the same period in 2025.” “The Company intends to use the net proceeds from the offering for (i) the manufacture of clinical drug supply, (ii) the Company’s current clinical trial activities, (iii) the Company’s planned Phase 3 clinical trial activities, and (iv) working capital purposes.”
“|| ● | Research and development expenses for the three months ended June 30, 2026 were approximately $589,000, compared to $1.2 million during the same period in 2025.”
Focus on manufacturing clinical drug supply and conducting Phase 3 clinical trials for Ampligen.
Over the trailing year it converted 0.78x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
37 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.